A study to evaluate the safety and efficacy of Novel oral anticoagulation (Apixaban or rivaroxaban) in patients with CF-LVADs after failed warfarin therapy
Latest Information Update: 08 May 2019
At a glance
- Drugs Apixaban (Primary) ; Rivaroxaban (Primary)
- Indications Thromboembolism
- Focus Adverse reactions
Most Recent Events
- 08 May 2019 New trial record
- 06 Apr 2019 Results presented at the 39th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation